Abuse-resistant amphetamine prodrugsCAFC
1. A pharmaceutical composition comprising (a) L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable additive.
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
- 1. A pharmaceutical composition comprising (a) L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable additive.
- 12. A pharmaceutical composition comprising L-lysine-d-amphetamine dimesylate and a pharmaceutically acceptable additive, wherein said pharmaceutical composition has a water content of about 1% to about 10% by Karl Fischer analysis.